# Aurobindo Pharma: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Aurobindo Pharma Limited · NSE: AUROPHARMA · BSE: 524804 · Sector: Healthcare

Updated for Q2 FY27 · checked 17 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/aurobindo-pharma. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Aurobindo Pharma: how the business works", with the page URL.

## In short

Buyers in the US, Europe and other countries pay Aurobindo for generic medicines and drug ingredients. Most of the money goes on materials, staff and running costs. In FY26, ₹10.3 of every ₹100 that came in was left as profit.

- In FY26 customers in the US paid 42.7% of Aurobindo's revenue, Europe 31.8%, other countries 15.7% and India 9.9%.
- Of every ₹100 that came in during FY26, ₹39.5 went on materials and goods bought, ₹15.2 on staff and ₹23.8 on other running costs.

## Key facts

**What does Aurobindo Pharma do?**

Aurobindo Pharma, based in Hyderabad, makes generic medicines (copies of medicines whose patents have ended) and the active ingredients that go into them. In FY26 its US medicine sales were ₹14,408 crore and its Europe sales ₹10,315 crore. [S1, S13]

**How does Aurobindo Pharma make money?**

Aurobindo Pharma earns most of its money selling finished medicines (formulations): ₹29,606 crore, 88.0% of FY26 revenue. Sales of drug ingredients (APIs) to other drug makers brought in ₹4,047 crore, 12.0%. [S13]

**Who pays Aurobindo Pharma?**

In FY26 customers in the US paid 42.7% of Aurobindo Pharma's ₹33,653 crore revenue, Europe 31.8%, other countries 15.7% and India 9.9%. No single customer paid 10% or more of its FY26 revenue. [S1]

**How big is Aurobindo Pharma?**

Aurobindo Pharma reported FY26 revenue of ₹33,653 crore and profit to shareholders of ₹3,505 crore. Its FY26 sustainability report lists 28 plants in India and 5 abroad, and more than 27,000 permanent employees on 31 Mar 2026. [S1]

**Who owns Aurobindo Pharma?**

On 30 Sep 2026 the promoter group owned 51.88% of Aurobindo Pharma, Indian institutions 24.42%, foreign investors 17.41% and others 6.29%. Aurobindo Pharma's promoters had pledged 11.99% of their shares, equal to 6.22% of all shares. [S30]

**How much debt does Aurobindo Pharma have?**

On 31 Mar 2026 Aurobindo Pharma had borrowings of ₹7,676 crore and cash and liquid investments of ₹10,618 crore, so it held ₹2,941 crore more cash than debt (Cityfort calculation). [S1]

**How did Aurobindo Pharma do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Aurobindo Pharma's revenue rose 23.9% from a year earlier to ₹10,263 crore, and profit to shareholders was ₹1,126 crore against ₹848 crore. The quarter includes Lannett, bought on 29 Jun 2026. [S7, S8, S39]

**What has Aurobindo Pharma bought recently?**

Aurobindo Pharma completed its purchase of US generics maker Lannett on 29 Jun 2026, at an enterprise value of US$250 million. It also bought a Khandelwal Laboratories business in India (₹325 crore, agreed Jan 2026) and 80% of A1 Biochem's contract research business (Oct 2026). [S33, S39, S34, S41, S43]

## What does Aurobindo Pharma sell?

Aurobindo makes generic medicines: cheaper copies of medicines whose patents have ended. Most are sold in the US and Europe. It also makes APIs, the active chemicals inside medicines, and sells some to other drug makers.

- **US formulations:** Finished generic medicines sold in the US, including injectables made by its subsidiary Eugia. ₹14,408 crore in FY26, 42.8% of revenue. Since 29 Jun 2026 this includes Lannett. [S13, S39]
- **Europe formulations:** Generic medicines sold in European countries. ₹10,315 crore in FY26, 30.7% of revenue; the company said sales passed €1 billion in FY26. [S13]
- **Growth markets:** Medicines for other countries, including India. ₹3,499 crore in FY26; India's own branded medicines were ₹302 crore of it. [S13]
- **ARV:** Antiretroviral medicines, used to treat HIV. ₹1,384 crore in FY26, 4.1% of revenue. [S13]
- **APIs:** Active ingredients sold to other drug makers: ₹2,972 crore of beta-lactam APIs (penicillin-family antibiotics) and ₹1,075 crore of others in FY26. [S13]
- **Biosimilars and contract manufacturing:** Copies of biological medicines: 14 in the portfolio in FY26, 4 launched by Q2 FY27. Its unit TheraNym is building plants to make biologics for MSD. [S1, S8, S36]

## Who pays Aurobindo Pharma?

- **Customers in the US (42.7% of revenue):** Generic tablets, capsules and injectables. The FY26 sustainability report lists generic customers, major pharma companies, institutions and health care professionals as customer types. [S1]
- **Customers in Europe (31.8% of revenue):** Generic medicines sold in European countries. Europe's share rose from 29.1% in FY25 to 31.8% in FY26 (Cityfort calculation). [S1]
- **Customers in other countries (15.7% of revenue):** Medicines, HIV medicines and APIs sold outside the US, Europe and India. [S1]
- **Customers in India (9.9% of revenue):** Includes APIs sold to Indian drug makers as well as branded medicines. [S1, S13]
- **Customer concentration:** No single customer paid Aurobindo 10% or more of its revenue in FY26 or FY25, according to the segment note. Shares are of FY26 revenue by customer location (Cityfort calculation from the annual report's figures). [S1]

## Where the money went (FY26)

1. In FY26 Aurobindo took in ₹33,653 crore from sales plus ₹492 crore of other income.
2. Materials and goods bought for resale cost ₹13,488 crore, the largest cost.
3. Staff cost ₹5,190 crore and other running costs ₹8,129 crore.
4. Depreciation took ₹1,778 crore, interest ₹384 crore and tax ₹1,609 crore.
5. ₹3,505 crore was left for Aurobindo's shareholders.

Sources: S1.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 23,455 | 4,228 | 18.0% | 2,648 | 11.3% | 45.19 | 5,016 | 2,705 | 2,312 | S4 |
| FY23 | 24,855 | 3,707 | 14.9% | 1,928 | 7.8% | 32.9 | 2,387 | 2,720 | −334 | S3 |
| FY24 | 29,002 | 5,634 | 19.4% | 3,173 | 10.9% | 54.16 | 2,435 | 3,562 | −1,127 | S3 |
| FY25 | 31,724 | 6,551 | 20.7% | 3,486 | 11.0% | 59.81 | 3,925 | 2,520 | 1,405 | S1 |
| FY26 | 33,653 | 6,782 | 20.2% | 3,505 | 10.4% | 60.34 | 5,526 | 3,105 | 2,422 | S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 31 Mar 2026, ₹ crore)

On 31 Mar 2026 Aurobindo's cash and liquid investments were ₹2,941 crore more than its borrowings. [S1, S8]

| Item | Value |
| --- | --- |
| Total debt | 7,676 |
| Cash and investments | 10,618 |
| Net debt (debt minus cash) | −2,941 |
| Net worth (shareholders' money) | 37,891 |
| Debt to equity (times) | 0.2 |

- Borrowings exclude lease liabilities (rent owed under leases) of ₹397 crore.
- Cash and liquid investments = cash ₹7,191 crore + other bank balances ₹2,679 crore + current investments ₹747 crore. Net debt is a Cityfort calculation.
- The company's own measure, which also counts non-current investments, showed net cash of ₹1,812 crore (US$189 million) on 30 Sep 2026, with gross debt of ₹8,232 crore.
- Net worth is the equity belonging to Aurobindo shareholders on 31 Mar 2026, before the 2026 buyback.

## Who owns Aurobindo Pharma? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 51.88% |
| Promoter shares pledged (% of promoter shares) | 11.99% |
| Foreign institutions (FII) | 17.41% |
| Indian institutions (DII) | 24.42% |
| Public | 6.29% |

Sources: S30, S29, S28, S27, S26, S25, S24, S23, S22, S21, S20.

## What could go wrong

### US FDA plant actions

Eugia Unit-I received a US FDA warning letter on 14 Aug 2026; the company said it gives about 2% of group revenue. Eugia Unit-III and Lannett's Seymour plant were classified OAI in 2026. [S42, S38, S45]

What to watch: Re-inspections, and any new warning letter or import restriction at these three plants.

### Reliance on US generics

US formulations were 42.8% of FY26 revenue. US sales fell from ₹14,816 crore in FY25 to ₹14,408 crore in FY26; management said lower generic Revlimid sales held growth back. [S13, S15, S7]

What to watch: US formulation sales each quarter: ₹4,555 crore in Q2 FY27, including Lannett.

### Promoter pledge

Promoters had pledged 11.99% of their shares on 30 Sep 2026, down from 23.65% on 31 Mar 2026. Lenders can sell pledged shares if the loans are not repaid. [S30, S28]

What to watch: The pledged share count in each quarterly shareholding filing.

### Lannett integration

Aurobindo paid an enterprise value of US$250 million for Lannett, completed on 29 Jun 2026. Its sales are not shown separately, and its Seymour plant was classified OAI on 11 Nov 2026. [S33, S39, S45]

What to watch: Whether the company reports Lannett's sales, and the Seymour plant's status.

### Currency swings

International sales were 92% of Q2 FY27 revenue. Europe sales rose 27.5% in rupees but 18% in euros in Q2 FY27, so currency moves changed the reported growth. [S7]

What to watch: Growth in US dollars and euros beside rupee growth in each press release.

### Large new projects

Capital spending was ₹3,105 crore in FY26. The TheraNym biologics plants for MSD include a second unit that the company's Q2 FY27 presentation (4 Nov 2026) puts at about US$180 million, ready for qualification in 2030. [S1, S8]

What to watch: TheraNym Unit 1 qualification, which the company said on 4 Nov 2026 it expects by Mar 2027.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Plant inspections:** Progress on the Eugia Unit-I warning letter (14 Aug 2026) and the OAI status of Eugia Unit-III and Lannett's Seymour plant.
- **FY27 guidance:** Management said on 5 Nov 2026 it expects double-digit FY27 revenue growth and EBITDA above ₹8,000 crore; H1 FY27 EBITDA was ₹4,037 crore on its own measure.
- **Promoter pledge:** Promoters had pledged 11.99% of their shares on 30 Sep 2026; the Dec 2026 shareholding filing shows the next figure.

## Sources

- S1: Integrated Annual Report 2025-26 (FY26). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/annualreports/Aurobindo-Pharma-IR-2026_For-web.pdf (published 6 Aug 2026)
- S2: Annual Report 2024-25 (FY25). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/annualreports/AurobindoPharmaIR2025-website.pdf (published 8 Aug 2025)
- S3: Annual Report 2023-24 (FY24). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/annualreports/AurobindoPharmaLimited-AnnualReport2023-24.pdf (published 25 May 2024)
- S4: Annual Report 2022-23 (FY23). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/annualreports/AurobindoIR22-23_IR_Final_Web.pdf (published 27 May 2023)
- S5: Annual Report 2021-22 (FY22). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/annualreports/Aurobindo-Pharma-AR-2021-22-4.pdf (published 30 May 2022)
- S6: Unaudited financial results, Q2 FY27 (quarter ended 30 Sep 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/Financial%20Results_Q2%20FY2026-27.pdf (published 4 Nov 2026)
- S7: Press release, Q2 FY27 results. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/PressRelease_Q2FY27.pdf (published 4 Nov 2026)
- S8: Earnings presentation, Q2 FY27. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/Earnings-Presentation_Q2FY27.pdf (published 4 Nov 2026)
- S9: Q2 FY27 earnings call transcript (call of 5 Nov 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/conferencecalltranscripts/AUROPHARMA_ECT_Q2FY27.pdf (published 11 Nov 2026)
- S10: Press release, Q1 FY27 results. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/APL_PressRelease_Q1FY27.pdf (published 5 Aug 2026)
- S11: Earnings presentation, Q1 FY27. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/APL_EarningsPresentation_Q1FY27.pdf (published 5 Aug 2026)
- S12: Q1 FY27 earnings call transcript (call of 6 Aug 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/conferencecalltranscripts/APL_ECT_Q1FY27_Final.pdf (published 13 Aug 2026)
- S13: Press release, Q4 FY26 and FY26 results. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/APL_PressRelease_Q4FY26.pdf (published 21 May 2026)
- S14: Earnings presentation, Q4 FY26. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/APL_EarningsPresentation_Q4FY26.pdf (published 21 May 2026)
- S15: Q4 FY26 earnings call transcript (call of 22 May 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/conferencecalltranscripts/Aurobindo_Transcript_Q4FY26.pdf (published 22 May 2026)
- S16: Press release, Q3 FY26 results. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/APL_Press%20Release_Q3FY26.pdf (published 9 Feb 2026)
- S17: Earnings presentation, Q3 FY26. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/APL%20-%20Earnings%20Presentation%20Q3FY26.pdf (published 9 Feb 2026)
- S18: Q3 FY26 earnings call transcript (call of 10 Feb 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/conferencecalltranscripts/Transcript_Q3FY26_Final.pdf (published 10 Feb 2026)
- S19: Press release, Q4 FY24 and FY24 results. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/resultsannouncement/LtrToSEsPressRelease25052024.pdf (published 25 May 2024)
- S20: Shareholding pattern as of 31 Mar 2024 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareholdingPatternAurobindo31.03.2024.pdf (published 31 Mar 2024)
- S21: Shareholding pattern as of 30 Jun 2024 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareHoldingPattern30062024.pdf (published 30 Jun 2024)
- S22: Shareholding pattern as of 30 Sep 2024 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareHoldingPattern30092024.pdf (published 30 Sep 2024)
- S23: Shareholding pattern as of 31 Dec 2024 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareholdingPattern31122024.pdf (published 31 Dec 2024)
- S24: Shareholding pattern as of 31 Mar 2025 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareHoldingPatternAPL31032025.pdf (published 31 Mar 2025)
- S25: Shareholding pattern as of 30 Jun 2025 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareHoldingPattern30062025withoutPAN.pdf (published 30 Jun 2025)
- S26: Shareholding pattern as of 30 Sep 2025 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/APLShareholdingPattern30092025.pdf (published 30 Sep 2025)
- S27: Shareholding pattern as of 31 Dec 2025 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareholdingPattern31122025.pdf (published 31 Dec 2025)
- S28: Shareholding pattern as of 31 Mar 2026 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShPattern31032026-website.pdf (published 31 Mar 2026)
- S29: Shareholding pattern as of 30 Jun 2026 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/ShareholdingPattern30.06.2026.pdf (published 30 Jun 2026)
- S30: Shareholding pattern as of 30 Sep 2026 (Reg. 31). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/AUROBINDO_ShPattern30092026forWebsite.pdf (published 15 Oct 2026)
- S31: India Ratings rating letter: bank facilities affirmed IND AA+/Stable/IND A1+. India Ratings and Research (letter hosted on company IR site). https://www.aurobindo.com/api/uploads/AurobindoPharmaLtd_RatingLetter-28244.pdf (published 11 Mar 2025)
- S32: NSE CM bhavcopy, 13 Nov 2026 (AUROPHARMA EQ close). National Stock Exchange of India. https://nsearchives.nseindia.com/content/cm/BhavCopy_NSE_CM_0_0_0_20261113_F_0000.csv.zip (published 13 Nov 2026)
- S33: Reg. 30 disclosure: agreement to acquire Lannett Company (EV US$250 million). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsLannett30072025.pdf (published 30 Jul 2025)
- S34: Reg. 30 disclosure: business transfer of Khandelwal Laboratories non-oncology formulations business. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsAuroPharmaAcquisition01012026.pdf (published 1 Jan 2026)
- S35: Outcome of board meeting: buyback of up to 54,23,728 shares at INR 1,475. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsOutomeBoardMeeting06042026.pdf (published 6 Apr 2026)
- S36: TheraNym Biologics: additional product schedule with MSD. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsTheranymMSDagreement15042026.pdf (published 15 Apr 2026)
- S37: Reg. 30 disclosure: Telangana High Court order on promoter-group SEBI settlement matter. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsOrderHighCourtSEBIPIT16052026.pdf (published 16 May 2026)
- S38: Eugia Unit-III (Pashamylaram) US FDA inspection classified OAI. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsEuigaUnit3USFDAinspection12062026.pdf (published 12 Jun 2026)
- S39: Completion of Lannett acquisition (effective 29 Jun 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsLannettAcquistionCompletion30062026.pdf (published 30 Jun 2026)
- S40: Completion of transfer of domestic branded generics business to Auropharm Ltd (w.e.f. 1 Jul 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsAuroPharmAcquistionCompletion02072026.pdf (published 2 Jul 2026)
- S41: Reg. 30 disclosure: Apitoria to acquire 80% of A1 Biochem contract research business (EV US$17 million). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrSEsA1BiochenAcquisition23072026.pdf (published 23 Jul 2026)
- S42: Eugia Unit-I receives US FDA warning letter. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsEugiaUnitIWarningLetter14082026.pdf (published 14 Aug 2026)
- S43: Completion of A1 Biochem acquisition. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsA1BiochemCompletionofAcquisition02102026.pdf (published 2 Oct 2026)
- S44: Interim dividend of INR 7 per share for FY27 (record date 11 Nov 2026). Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsDividendUpdate04112026.pdf (published 4 Nov 2026)
- S45: Lannett (Seymour, IN) US FDA inspection classified OAI. Aurobindo Pharma Ltd (company IR site). https://www.aurobindo.com/api/uploads/disclosureofeventsinformation/LtrToSEsLannetUSFDA11112026.pdf (published 11 Nov 2026)
